[Form 4] CME Group Inc. Insider Trading Activity

Rhea-AI Filing Summary

CME Group director Patrick J. Mulchrone reported insider trading activity on June 25, 2025. Key details of the transaction include:

• Acquired 532 shares of Class A Common Stock at $273.03 per share through the CME Group Director Stock Plan
• Following the transaction, Mulchrone directly owns 28,485 shares
• Additionally holds 25,000 shares indirectly through spouse

The Form 4 filing indicates this was a planned acquisition under the company's director compensation program rather than an open market transaction. The filing was submitted by Jenelle Chalmers on behalf of Mulchrone on June 26, 2025, within the required reporting timeframe.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mulchrone Patrick J

(Last) (First) (Middle)

20 S. WACKER DR.

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2025		A(1)		532	A	$273.03	28,485	D
Common Stock Class A								25,000	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Granted pursuant to the CME Group Director Stock Plan, as amended and restated.

Remarks:

	By: Jenelle Chalmers For: Patrick J. Mulchrone	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CME Group shares did Director Patrick Mulchrone acquire on June 25, 2025?

According to the Form 4 filing, Director Patrick Mulchrone acquired 532 shares of CME Group Class A Common Stock on June 25, 2025, at a price of $273.03 per share.

What is the total CME stock ownership of Patrick Mulchrone after the June 2025 transaction?

Following the transaction, Patrick Mulchrone owns 28,485 shares directly and 25,000 shares indirectly through his spouse, for a total beneficial ownership of 53,485 CME Group Class A shares.

How were the new CME shares granted to Director Mulchrone in June 2025?

The shares were granted pursuant to the CME Group Director Stock Plan, as amended and restated, as indicated in the footnotes of the Form 4 filing.

Who filed the Form 4 for CME Director Mulchrone?

The Form 4 was filed by Jenelle Chalmers on behalf of Patrick J. Mulchrone on June 26, 2025, one day after the transaction date.

What is Patrick Mulchrone's role at CME Group according to the Form 4?

According to the Form 4 filing, Patrick J. Mulchrone serves as a Director of CME Group Inc., as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.